Skip to main content

Back to home

BLADDR 2018

BLADDR2016

The Global Congress on Bladder Cancer brings together top experts and delegates from several disciplines, for an in-depth discussion of the different aspects of bladder cancer, with a focus on difficulties and dilemmas of clinical decision making, settled in an inspiring location.

1

Emerging role of interaction between cell cycle protein expression by tumor cells and M2-macrophage infiltration in urinary bladder cancer

Aljabery
Firas
Linkoping University Hospital
Linkoping
Sweden
2

The role of nursery in bladder cancer

Amador Robayna
Adrián
University Hospital Nuestra Señora de Candelaria
Santa Cruz de Tenerife
Spain
3

EVALUATION OF BLADDER LESIONS USING SMARTPHONES IN VIDEO CYSTOURETHROSCOPY

ARADA
ERNESTO III
Quirino Memorial Medical Center
Quezon City
Philippines
4

Comparation Between Body Mass Index and Side Effect Incidence In Bladder Cancer Patients Treated With Gemcitabine-Cisplatin At Dr. Saiful Anwar General Hospital Malang, Indonesia

Ardiani
Astarin
Dr. Saiful Anwar General Hospital
Malang
Indonesia
5

Prognostic implications of the loss of heterozygosity in the regions 9p21-22 and 9q33-34 in patients with bladder cancer.

Ballesta
Begoña
Hospital Universitario Nuestra Señora de Candelaria
SC de Tenerife
Spain
6

Association of the loss of heterozygosity in D9S66 and smoking in patients with bladder cancer.

Ballesta
Begoña
Hospital Universitario Nuestra Señora de Candelaria
SC de Tenerife
Spain
7

What are the main predictors of Post-Operatory Complications after Radical Cystectomy and Urinary Diversion?

Bernardino
Rui
Centro Hospitalar de Lisboa Central
Lisbon
Portugal
8

Robot assisted Radical Cystoprostatectomy with total Intracorporeal Orthotopic Ileal Neobladder Urinary Diversion: Technical considerations

Bhaskar
Ved
Medanta
Gurgaon
India
9

A case for reducing palliative bladder radiotherapy margins?

Brooks
Rachel
Freeman Hospital
Newcastle upon Tyne
United Kingdom
10

Neutrophil Lymphocyte ratio as a marker in urinary bladder cancer: The Indian experience

Chandna
Abhishek
Post Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh
India
11

Preliminary experience in the use of Hyperthermic Intravesical Chemotherapy to treat BCG-Unresponsive high-grade non-muscle invasive bladder cancer.

Chiancone
Francesco
AORN A.Cardarelli
Naples
Italy
12

UNUSUAL METASTASIS IN MUSCLE-INVASIVE BLADDER CARCINOMA

Damas Arroyo
Francisco
Hospital General Universitario de Ciudad Real
Ciudad Real
Spain
13

Monopolar transurethral resection of bladder tumors preformed by a urology resident: Is is safe for the patient?

Damas Arroyo
Francisco
Hospital General Universitario de Ciudad Real
Ciudad Real
Spain
14

EGFR cell expression during adjuvant treatment after transurethral resection for non muscle-invasive bladder cancer

Di Maida
Fabrizio
Azienda Ospedaliera Universitaria Careggi
Firenze
Italy
15

VISTA, PHASE 3 TRIAL OF VICINIUM, AN EPCAM-TARGETED PSEUDOMONAS EXOTOXIN, IN BCG-UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER

Dickstein
Rian
Chesapeake Urology
Baltimore
USA
16

Laparoscopic Radical Cystectomy in the Elderly: Analysis of a Single Center.

Dmitry
Semenov
Oncodispensary
Saint-Petersburg
Russia
17

Analysis of the perioperative and oncological outcome of 164 cases of laparoscopic radical cystectomy: a single center experience.

Dmitry
Semenov
Oncodispensary
Saint-Petersburg
Russia
18

CAN THE COMBINATION OF LAPAROSCOPY AND A MULTIMODAL ENHANCED RECOVERY PROTOCOL IMPROVE PERIOPERATIVE OUTCOMES IN RADICAL CYSTECTOMY? RESULTS OF A SINGLE-CENTER EXPERIENCE

Domínguez
Arturo
Hospital Universitari Parc Taulí
Sabadell
Spain
19

Atezolizumab (atezo) as first-line (1L) therapy in patients (pts) with cisplatin (cis)-ineligible locally advanced or metastatic urothelial cancer (mUC): efficacy by PD-L1 status over time from IMvigor210 Cohort 1

Durán
Ignacio
Hospital Universitario Marques de Valdecilla
Santander
Spain
20

Expression of Her2-neu, SKP2 and HIF-1 and their role in predicting the response of muscle invasive urothelial carcinoma to bladder- preservation chemotherapy

Elkhouly
Enas
Menoufia University
Menoufia
Egypt
21

Evaluation of Topoisomerase II, Ki-67 and P53 expression in non-muscle invasive urothelial carcinoma and their clinical significance

Elkhouly
Enas
Menoufia University
Menoufia
Egypt
22

The Studer Orthotopic Neobladder: 4 years functional outcomes and complications

falcao
gil
centro hospitalar de lisboa central
lisbon
portugal
23

The Applicability of the EORTC Scoring System and Risk Tables for the Prediction of Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer in Indian Population

G R
MANJUNATH
INSTITUTE OF NEPHROUROLOGY
BANGALORE
India
24

High risk non muscle invasive bladder cancer: more options than BCG?

Garcia Alvarez
Carlos
University Hospital of Canary Island
La Laguna
Spain
25

URACHAL PATHOLOGY: REVIEW OF CASES

García García
Ana Lorena
Nuestra Señora de Candelaria
Santa Cruz de Tenerife
Spain
26

Chemohyperthermia with Mitomycin C in patients with non-muscle-invasive bladder cancer, initial experience in a single center.

González
Daniel
Hospital Universitario 12 de Octubre
Madrid
Spain
27

BCG vs chemohyperthermia with mitomycin C for high-risk non-muscle invasive bladder carcinoma: preliminary results of HIVEC-HR randomized clinical trial

Guerrero-Ramos
Félix
Hospital Universitario 12 de Octubre
Madrid
Spain
28

Bladder cancer in the "Golden Years"

Hill
George
Bristol Urological Institute, Southmead Hospital
Bristol
United Kingdom
29

Accuracy of magnetic resonance imaging for local staging of bladder cancer during the learning curve

Jiménez Navarro
M.
University Hospital Nuestra Señora de La Candelaria
Santa Cruz de Tenerife
Spain
30

Anxiety and pain during cystoscopy

Jiménez Navarro
M.
University Hospital Nuestra Señora de La Candelaria
Santa Cruz de Tenerife
Spain
31

Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients With Metastatic or Surgically Unresectable Urothelial Carcinoma and Selected FGFR Gene Alterations - the Phase 3 THOR Study

Loriot
Yohann
Institut Gustave Roussy
Villejuif
France
32

Vangl2 overexpression increases apoptosis and affects inflammation in Jurkat t-cells

Lindqvist
Maria
Karolinska university hospital
Stockholm
Sweden
33

Hyperthermic intravesical chemotherapy with Mitomycin C in high risk non-muscle invasive bladder cancer patients

Lysenko
Victoria
University clinic of Odessa National Medical University
Odesa
Ukraine
34

Histopathological analysis of cystoprostatectomy specimen- a unique opportunity to study silent adenocarcinoma of prostate in patients of bladder cancer

MAHADIK
RAJAT
AMRITA HOSPITAL AND MEDICAL COLLEGE (AIMS)
KOCHI
INDIA
35

Hyperprogression after Immunotherapy in Patient with Recurrent and Metastatic Urothelial Bladder Carcinoma following Cisplatin-based First-line Chemotherapy: a Case Report

Mao
Shiyu
Shanghai Tenth People's Hospital
Shanghai
China
36

Oncologic impact of preoperative hypoalbuminemia in elderly patients treated with Radical Cystectomy for urothelial bladder cancer

Mari
Andrea
Azienda Ospedaliera Universitaria Careggi
Firenze
Italy
37

PROGRESSION TO INVASIVE MUSCLE STADIUM IN UROTHELIAL TUMORS: COMBINATION OF PROGNOSTIC FACTORS AND THEIR IMPACT ON PROPHYLATIC TREATMENT

Moyano Calvo
José Luis
Hospital Universitario Virgen Macarena
Seville
Spain
38

LYMPHOVASCULAR PERMEATION AS A PRONOSTIC PROGRESSION FACTOR IN T1G3 BLADDER TUMORS TREATED WITH BCG.

Moyano Calvo
José Luis
Hospital Universitario Virgen Macarena
Seville
Spain
39

Transcription Factor E2F1 Is Associated with the Homologous Recombination Activity by RAD54L in Bladder Cancer Progression.

Mun
Mi-Hye
Dong-A University
Busan
Korea
40

Isolation and characterization of urinary extracellular vesicles: their potential as source of biomarkers for urological malignancies

Oeyen
Eline
University of Antwerp
Antwerp
Belgium
41

Upper urinary tract urothelial carcinoma. Diagnosis and prognosis factors with computed tomography

Orribo Morales
Nuria
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife
Spain
42

Upper Urinary Tract Urothelial Carcinoma. Our Epidemiology

Orribo Morales
Nuria
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife
Spain
43

Adrenalectomy for metastasis of bladder Cancer. A case report

Orribo Morales
Nuria
Hospital Universitario Nuestra Señora de Candelaria
Santa Cruz de Tenerife
Spain
44

Comparation Between Gemcitabine-Cisplatin Chemotherapy Outcome and Body Mass Index in Muscle Invasive Bladder Cancer Patients At Dr. Saiful Anwar General Hospital Malang, Indonesia

Penta Seputra
Kurnia
Dr. Saiful Anwar General Hospital
Malang
Indonesia
45

An unusual presentation of an external urethral mass

Robinson
Simon
Frimley Health Foundation Trust
Frimley
United Kingdom
46

Variation in tumour volume of bladder cancer among histological subtypes

Robinson
Simon
Frimley Health Foundation Trust
Frimley
United Kingdom
47

A comparison of mortality rates and tumour characteristics for squamous cell and transitional cell cancer of the bladder.

Robinson
Simon
Frimley Health Foundation Trust
Frimley
United Kingdom
48

Metastasis of Ta Low-grade Bladder Cancer into the Lung and paraneoplastic syndrome without local invasion: a very rare case

Rodríguez López
Sabela
HGUCR
Ciudad Real
Spain
49

Pseudomyxoma peritonei secundary to urachal mucinous tumour treated by cytoreductive surgery plus HIPEC with turbulent-flow CO2 circuit

Rodríguez López
Sabela
HGUCR
Ciudad Real
Spain
50

Intravesical bacillus Calmette-Guerin complications in our centre

Rodríguez López
Sabela
HGUCR
Ciudad Real
Spain
51

Introducing PDD and IMAGE1 S guided diode laser treatment of intermediate-risk non-invasive bladder tumors to the outpatient department.

Schmidt Erikson
Marie
Herlev and Gentofte University Hospital
Copenhagen
Denmark
52

Neutrophil-to-lymphocyte ratio predicts the 5-year recurrence of bladder cancer after transurethral resection of bladder tumor

Seo
Jaeho
St. Paul's Hospital, The Catholic University of Korea, College of Medicine
Seoul
South Korea
53

Clinical Value of C - reactive protein And Erythrocyte Sedimentation Rate in Advanced Bladder Cancer

shehata
mohamed
menoufia university hospital
shibin el kom
egypt
54

W-shaped ileal orthotopic neobladder with serosa lined tunneled uretero-ileal anastomosis (Ghoneim’s pouch): Short term oncological, functional and urodynamic outcomes.

Singh
Uday Pratap
Sanjay Gandhi Post Graduate Institute of Medical Sciences
Lucknow
India
55

Saving bladders with brachytherapy using (robot assisted) laparoscopically performed implantations for solitary muscle invasive bladder tumors (MIBC)

Smits
Geert
Rijnstate Hospital
Arnhem
The Netherlands
56

Molecular Profiling Reveals Biologically Distinct Subgroups of Bladder Cancer with Different Sensitivities to Immunotherapy

Song
Bic-Na
Korea Research Institute of Bioscience and Biotechnology
Daejeon
Korea
57

A NOVEL STRATEGY OF INTRAOPERATIVE USE OF TOPICAL NOREPINEPHRINE, TRANEXAMIC ACID AND ENDO CUTTER STAPLERS FOR REDUCING BLOOD LOSS DURING OPEN RADICAL CYSTECTOMY

Talwar
Harkirat
PGIMER
CHANDIGARH
India
58

Chemohypertermia with Mitomycin C (MMC) and COMBAT system in High Risk Non Muscle Invasive Bladder Cancer (HR NMIBC): A new alternative?

Villacampa
Felipe
Clinica Universidad de Navarra
Madrid
Spain
59

CELLDETECT® IMPROVES PERFORMANCE OF BLADDER CANCER DIAGNOSIS COMPARED TO STANDARD CYTOLOGY AND FISH

Wilchfort
Billie
Micromedic Technologies Ldt
Tel-Aviv
Israel
60

Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy

Zajac
Magdalena
AstraZeneca
Cambridge
United Kingdom